Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Support side: Insider open-market buy — insiders or holders bought while this setup is live; see the timeline.
Radar 93 (high attention) · dilution pressure elevated · listing risk high · governance risk low · runway 1.3 mo · strongest signal: MVLS deficiency (Jul 29, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 77 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Jul 31, 2026 | · Form 4 burst | 6 Form 4 filings in 30 days filing | 15 |
| Jul 30, 2026 | ▲ Insider open-market buy | 2 open-market buys by 1 insider(s) (~$51,982) in 30d: GEYGAN JEFFREY RICHART 6,[email protected] 2026-07-29; GEYGAN JEFFREY RICHART 62,[email protected] 2026-07-30 filing | 26 |
| Jul 29, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-07-29 filing | 63 |
| Jul 29, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-07-29 (accepted 16:32 ET) filing | 60 |
| Jul 29, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-07-29 filing | 48 |
| Jul 29, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-07-29 filing | 46 |
| May 31, 2026 | ▼ Runway < 6 months | ~1.3 months runway: liquidity $1,063,000 as of 2026-05-31, burn $10,110,000/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing | 43 |
| May 31, 2026 | ▼ Negative equity | Stockholders' equity $-12,018,000 as of 2026-05-31 filing | 31 |
| May 31, 2026 | ▼ Cash < current liabilities | Liquidity $1,063,000 vs current liabilities $3,168,000 filing | 21 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →